This is a very touching point for me, because unfortunately, the role of cord blood transplant has changed over the years. And both in Europe and in the United States, there has been a decline in the use of cord blood as a source of stem cells for transplantation. That is due to several reasons. The main one being the fact that the use of post-transplant cyclophosphamide as a GVHD prophylaxis has allowed us to use different donors like haploidentical donors and mismatched unrelated donors...
This is a very touching point for me, because unfortunately, the role of cord blood transplant has changed over the years. And both in Europe and in the United States, there has been a decline in the use of cord blood as a source of stem cells for transplantation. That is due to several reasons. The main one being the fact that the use of post-transplant cyclophosphamide as a GVHD prophylaxis has allowed us to use different donors like haploidentical donors and mismatched unrelated donors. So the cord blood was very important in the past to be a resource for patients without a donor. But now that we have extended the donor pool using these other stem cell sources, the need for cord blood has diminished. And because it’s a different type of transplant compared to the others, unfortunately, many of my colleagues and transplant doctors tend to not utilize it. And my institution will be different because we’ve done this for several years now – it’s about 20 years that my program has started. And our outcomes are incredibly good, and therefore we kept doing it. But if we look at the general picture, the number of cord blood transplants done per year, both in the United States and Europe, is unfortunately declining.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
